Somatostatin receptor scintigraphy predicts impending cardiac allograft rejection before endomyocardial biopsy

European Journal of Nuclear Medicine

Volumn 27, Issue 12, 2000, Pages 1754-1759

  Aparici, Carina Mari ^a   Narula, Jagat ^b   Puig, Mireia ^b   Camprecios, Marta ^b   Martin, Juan C ^a   Tembl, Ana ^a   Flotats, Albert ^a   Estorch, Montse ^a   Catafau, Ana M ^a   Berna, Lluis ^a   Ballester, Manel ^b   Carrio, Ignasi ^a  

^a Sant Pau University Hospital   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

Author keywords

Allograft rejection; Heart transplantation; Somatostatin analogue; Somatostatin receptor scintigraphy

Indexed keywords

PENTETREOTIDE IN 111; SOMATOSTATIN RECEPTOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DISEASE SEVERITY; FEMALE; GRAFT REJECTION; HEART MUSCLE BIOPSY; HEART MUSCLE NECROSIS; HEART SCINTISCANNING; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; LYMPHOCYTE ACTIVATION; LYMPHOCYTIC INFILTRATION; MALE; TIME;

BIOPSY; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MIDDLE AGED; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RECEPTORS, SOMATOSTATIN; SOMATOSTATIN;

EID: 0033635327     PISSN: 03406997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002590000347     Document Type: Article

References (25)

1. Diagnosis of cardiac rejection by endomyocardial biopsy
2. Biopsia endomiocardica en los pacientes transplantados tratados con ciclosporina A
3. Noninvasive detection of acute heart rejection: The quest for the perfect test
4. Myocardial injury: Quantitation by cell sorting initiated with antimyosin fluorescent spheres
5. Monoclonal antibody to cardiac myosin: Imaging of experimental myocardial infarction
6. Noninvasive detection of human cardiac transplant rejection with In-111 antimyosin “Fab” imaging
7. Patterns of evolution of myocyte damage after human heart transplantation detected by indium 111 monoclonal antimyosin
8. The role of indium-111 antimyosin “Fab” imaging as a noninvasive surveillance method of human heart transplant rejection
9. 111In-monoclonal antimyosin antibody studies after the first year of heart transplantation: Identification of risk groups for developing rejection during long-term follow-up and clinical implications
10. Indium-111 monoclonal antimyosin for diagnosis of cardiac rejection
11. Detection of human cardiac transplant rejection with indium-111 monoclonal antimyosin antibody imaging
12. Ability of antimyosin scintigraphy monitoring to exclude acute rejection during the first year after heart transplantation
13. Evaluation of biopsy classification for rejection: Relation to detection of myocardial damage by monoclonal antimyosin antibody imaging
14. 111-Indium-antimyosin scintigraphy to assess myocardial damage in patients with suspected myocarditis and cardiac rejection
15. Antimyosin imaging in cardiac transplant rejection
16. Early postoperative reduction of monoclonal antimyosin uptake is associated with absent of rejection-related complications after heart transplantation
17. SSTR2A is the dominant somatostatin receptor subtype expressed by inflammatory cells, is widely expressed and directly regulates T cell IFN-γ release
18. Expression of somatostatin receptor subtype 2 mRNA in human lymphoid cells
19. Somatostatin receptors on human lymphocytes and leukaemia cells
20. Allograft rejection forecast: Somatostatin receptor imaging predicts impending rejection before biopsy becomes diagnostic
21. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group
22. Apoptosis of mononuclear cell infiltrates in cardiac allograft biopsy specimen question studies of biopsy-cultured cells
23. Detection of cardiac rejection by somatostatin receptor imaging